Monoclonal antibody + Tyrosine kinase inhibitorPhase 3 trialInvestigational

Pembrolizumab + Vemurafenib

How it works

Blocks PD-1 and BRAF, proteins involved in cell growth and division, which can help slow down cancer growth.

Cancer types

Melanoma— BRAF V600E mutation-positive

Efficacy

In clinical trials, around 50% of patients with BRAF V600E or V600K mutation achieved an objective response, with a median overall survival of approximately 22.5 months.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.